A Copenhagen biotech startup is betting big on Asia’s drinking culture. Now, Singapore will be the first test market.
Alcolase has raised €1.5 million to develop its enzyme-based solution for people suffering from alcohol intolerance – a condition affecting hundreds of millions across East Asia.
The Danish startup plans to launch first in Singapore before expanding into South Korea, where alcohol intolerance is widespread due to a genetic condition known as ALDH2 deficiency.
Founded in 2020 by Mikkel Precht, Jeppe Malthe Mikkelsen and Mads Emil Mikkelsen, the company is developing a technology designed to break down alcohol in the stomach before it enters the bloodstream.
For many people with ALDH2 deficiency, drinking alcohol can cause facial flushing, nausea and discomfort. The condition is also linked to increased health risks from alcohol consumption.
But according to Alcolase, the issue goes beyond physical symptoms.
In many Asian countries, social drinking plays a major role in business meetings, networking and family gatherings. People with alcohol intolerance may therefore feel excluded from important social and professional situations.
“When you speak to people with alcohol intolerance, you realise this is not about wanting to drink more. It is about not being shut out of dinners, work events and family gatherings because of a genetic difference,” said CEO and co-founder Mikkel Precht.
The investment round was backed by Ada Ventures, Delphinus Venture Capital, Antler, Manigoff Invest and several business angels.
Alcolase has also established a UK subsidiary to support the development of its delivery platform for therapeutic applications.
The company says the new funding will be used for further technology development, studies, patent strengthening and partnerships in key Asian markets.
